Follow
Stephen Atkin
Stephen Atkin
RCSI Bahrain
Verified email at rcsi.com
Title
Cited by
Cited by
Year
A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial
ES Kilpatrick, AS Rigby, SL Atkin
Diabetes care 31 (11), 2198-2202, 2008
5112008
Molecular mechanisms linking oxidative stress and diabetes mellitus
H Yaribeygi, T Sathyapalan, SL Atkin, A Sahebkar
Oxidative medicine and cellular longevity 2020, 2020
5022020
Insulin Resistance, the Metabolic Syndrome, and Complication Risk in Type 1 Diabetes: “Double diabetes” in the Diabetes Control and Complications Trial
ES Kilpatrick, AS Rigby, SL Atkin
Diabetes care 30 (3), 707-712, 2007
5002007
Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes
V Jayagopal, P Albertazzi, ES Kilpatrick, EM Howarth, PE Jennings, ...
Diabetes care 25 (10), 1709-1714, 2002
4822002
The effect of glucose variability on the risk of microvascular complications in type 1 diabetes
ES Kilpatrick, AS Rigby, SL Atkin
Diabetes care 29 (7), 1486-1490, 2006
4592006
Role of the NLRP3 inflammasome in cancer
M Moossavi, N Parsamanesh, A Bahrami, SL Atkin, A Sahebkar
Molecular cancer 17 (1), 158, 2018
3792018
Coexpression of estrogen receptor α and β: poor prognostic factors in human breast cancer?
V Speirs, AT Parkes, MJ Kerin, DS Walton, PJ Carleton, JN Fox, SL Atkin
Cancer research 59 (3), 525-528, 1999
3781999
Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients
V Speirs, C Malone, DS Walton, MJ Kerin, SL Atkin
Cancer research 59 (21), 5421-5424, 1999
3631999
Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone …
JS Bevan, SL Atkin, AB Atkinson, PM Bouloux, F Hanna, PE Harris, ...
The Journal of Clinical Endocrinology & Metabolism 87 (10), 4554-4563, 2002
3602002
The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26 …
L Meneghini, SL Atkin, SCL Gough, I Raz, L Blonde, M Shestakova, ...
Diabetes care 36 (4), 858-864, 2013
3352013
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial
JR Petrie, N Chaturvedi, I Ford, MCGJ Brouwers, N Greenlaw, T Tillin, ...
The lancet Diabetes & endocrinology 5 (8), 597-609, 2017
3182017
Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes
ES Kilpatrick, AS Rigby, K Goode, SL Atkin
Diabetologia 50, 2553-2561, 2007
2752007
Monocyte‐to‐HDL‐cholesterol ratio as a prognostic marker in cardiovascular diseases
S Ganjali, AM Gotto Jr, M Ruscica, SL Atkin, AE Butler, M Banach, ...
Journal of cellular physiology 233 (12), 9237-9246, 2018
2602018
Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a …
MJ Davies, SC Bain, SL Atkin, P Rossing, D Scott, MS Shamkhalova, ...
Diabetes care 39 (2), 222-230, 2016
2332016
The protective role of curcumin in myocardial ischemia–reperfusion injury
A Mokhtari‐Zaer, N Marefati, SL Atkin, AE Butler, A Sahebkar
Journal of cellular physiology 234 (1), 214-222, 2019
2222019
A review of the molecular mechanisms of hyperglycemia‐induced free radical generation leading to oxidative stress
H Yaribeygi, SL Atkin, A Sahebkar
Journal of cellular physiology 234 (2), 1300-1312, 2019
2202019
High‐cocoa polyphenol‐rich chocolate improves HDL cholesterol in Type 2 diabetes patients
DD Mellor, T Sathyapalan, ES Kilpatrick, S Beckett, SL Atkin
Diabetic medicine 27 (11), 1318-1321, 2010
2182010
The regulation and importance of monocyte chemoattractant protein-1
V Bianconi, A Sahebkar, SL Atkin, M Pirro
Current opinion in hematology 25 (1), 44-51, 2018
2152018
A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 …
MA Nauck, JR Petrie, G Sesti, E Mannucci, JP Courreges, ML Lindegaard, ...
Diabetes care 39 (2), 231-241, 2016
2122016
The obesity paradox in type 2 diabetes mellitus: relationship of body mass index to prognosis: a cohort study
P Costanzo, JGF Cleland, P Pellicori, AL Clark, D Hepburn, ES Kilpatrick, ...
Annals of internal medicine 162 (9), 610-618, 2015
2032015
The system can't perform the operation now. Try again later.
Articles 1–20